BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18260897)

  • 1. [Drug-eluting stent thrombosis and its pharmacological prevention].
    Pershukov IV; Batyraliev TA
    Kardiologiia; 2007; 47(7):60-7. PubMed ID: 18260897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies.
    Mohammad RA; Goldberg T; Dorsch MP; Cheng JW
    Clin Ther; 2010 Dec; 32(14):2265-81. PubMed ID: 21353100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of non-acute stent thrombosis after drug-eluting stent implantation].
    Gao YX; Li Y; Yu XZ; Li L; Li L; Yuan YQ; Zhao XY; Sun TW
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 May; 25(5):285-9. PubMed ID: 23663579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
    De Luca G; Dirksen MT; Spaulding C; Kelbaek H; Schalij M; Thuesen L; van der Hoeven B; Vink MA; Kaiser C; Musto C; Chechi T; Spaziani G; Díaz de la Llera LS; Pasceri V; Di Lorenzo E; Violini R; Cortese G; Suryapranata H; Stone GW;
    Arch Intern Med; 2012 Apr; 172(8):611-21; discussion 621-2. PubMed ID: 22529227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    Silber S; Kirtane AJ; Belardi JA; Liu M; Brar S; Rothman M; Windecker S
    Eur Heart J; 2014 Aug; 35(29):1949-56. PubMed ID: 24510638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
    Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
    Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
    Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
    Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
    Iakovou I; Schmidt T; Bonizzoni E; Ge L; Sangiorgi GM; Stankovic G; Airoldi F; Chieffo A; Montorfano M; Carlino M; Michev I; Corvaja N; Briguori C; Gerckens U; Grube E; Colombo A
    JAMA; 2005 May; 293(17):2126-30. PubMed ID: 15870416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis.
    Filion KB; Roy AM; Baboushkin T; Rinfret S; Eisenberg MJ
    Am J Cardiol; 2009 Feb; 103(3):338-44. PubMed ID: 19166686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies.
    Ishikawa T; Nakano Y; Endoh A; Kubota T; Suzuki T; Nakata K; Miyamoto T; Murakami M; Sakamoto H; Imai K; Mochizuki S; Yoshimura M; Mutoh M
    J Cardiol; 2009 Oct; 54(2):238-44. PubMed ID: 19782261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.